123 related articles for article (PubMed ID: 20497756)
1. Keratinocyte cancer prevention with ACE inhibitors, angiotensin receptor blockers or their combination in renal transplant recipients.
Moscarelli L; Zanazzi M; Mancini G; Rossi E; Caroti L; Rosso G; Bertoni E; Salvadori M
Clin Nephrol; 2010 Jun; 73(6):439-45. PubMed ID: 20497756
[TBL] [Abstract][Full Text] [Related]
2. Association of ACE inhibitors and angiotensin receptor blockers with keratinocyte cancer prevention in the randomized VATTC trial.
Christian JB; Lapane KL; Hume AL; Eaton CB; Weinstock MA;
J Natl Cancer Inst; 2008 Sep; 100(17):1223-32. PubMed ID: 18728281
[TBL] [Abstract][Full Text] [Related]
3. Melanoma and Non-Melanoma Skin Cancer Associated with Angiotensin-Converting-Enzyme Inhibitors, Angiotensin-Receptor Blockers and Thiazides: A Matched Cohort Study.
Nardone B; Majewski S; Kim AS; Kiguradze T; Martinez-Escala EM; Friedland R; Amin A; Laumann AE; Edwards BJ; Rademaker AW; Martini MC; West DP
Drug Saf; 2017 Mar; 40(3):249-255. PubMed ID: 27943160
[TBL] [Abstract][Full Text] [Related]
4. Renin angiotensin system blockade and activated vitamin D as a means of preventing deep vein thrombosis in renal transplant recipients.
Moscarelli L; Zanazzi M; Bertoni E; Caroti L; Rosso G; Farsetti S; Annunziata F; Paudice N; Salvadori M
Clin Nephrol; 2011 May; 75(5):440-50. PubMed ID: 21543024
[TBL] [Abstract][Full Text] [Related]
5. Cardiovascular death in kidney recipients treated with renin-angiotensin system blockers.
Opelz G; Döhler B
Transplantation; 2014 Feb; 97(3):310-5. PubMed ID: 24492421
[TBL] [Abstract][Full Text] [Related]
6. Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324,168 participants from randomised trials.
Bangalore S; Kumar S; Kjeldsen SE; Makani H; Grossman E; Wetterslev J; Gupta AK; Sever PS; Gluud C; Messerli FH
Lancet Oncol; 2011 Jan; 12(1):65-82. PubMed ID: 21123111
[TBL] [Abstract][Full Text] [Related]
7. Angiotensin receptor blockers (ARB) outperform angiotensin-converting enzyme (ACE) inhibitors on ischemic stroke prevention in patients with hypertension and diabetes - A real-world population study in Taiwan.
Pai PY; Muo CH; Sung FC; Ho HC; Lee YT
Int J Cardiol; 2016 Jul; 215():114-9. PubMed ID: 27111172
[TBL] [Abstract][Full Text] [Related]
8. Use of antihypertensive drugs and risk of keratinocyte carcinoma: A meta-analysis of observational studies.
Tang H; Fu S; Zhai S; Song Y; Asgari MM; Han J
Pharmacoepidemiol Drug Saf; 2018 Mar; 27(3):279-288. PubMed ID: 29318704
[TBL] [Abstract][Full Text] [Related]
9. Incidence of and Risk Factors for Severe Adverse Events in Elderly Patients Taking Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers after an Acute Myocardial Infarction.
Fang G; Annis IE; Farley JF; Mahendraratnam N; Hickson RP; Stürmer T; Robinson JG
Pharmacotherapy; 2018 Jan; 38(1):29-41. PubMed ID: 29059475
[TBL] [Abstract][Full Text] [Related]
10. Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers reduced dementia risk in patients with diabetes mellitus and hypertension.
Kuan YC; Huang KW; Yen DJ; Hu CJ; Lin CL; Kao CH
Int J Cardiol; 2016 Oct; 220():462-6. PubMed ID: 27390970
[TBL] [Abstract][Full Text] [Related]
11. Risk of Osteoporotic Fractures With Angiotensin II Receptor Blockers Versus Angiotensin-Converting Enzyme Inhibitors in Hypertensive Community-Dwelling Elderly.
Butt DA; Mamdani M; Gomes T; Lix L; Lu H; Tu K;
J Bone Miner Res; 2014 Nov; 29(11):2483-8. PubMed ID: 24806397
[TBL] [Abstract][Full Text] [Related]
12. Role of antihypertensive therapy with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers in combination with calcium channel blockers for stroke prevention.
Talbert RL
J Am Pharm Assoc (2003); 2010; 50(5):e116-25. PubMed ID: 20833609
[TBL] [Abstract][Full Text] [Related]
13. Angiotensin-converting enzyme inhibitor or angiotensin II type 1 receptor antagonist therapy is associated with prolonged patient and graft survival after renal transplantation.
Heinze G; Mitterbauer C; Regele H; Kramar R; Winkelmayer WC; Curhan GC; Oberbauer R
J Am Soc Nephrol; 2006 Mar; 17(3):889-99. PubMed ID: 16481415
[TBL] [Abstract][Full Text] [Related]
14. ACE inhibitors and angiotensin II antagonists in renal transplantation: an analysis of safety and efficacy.
Stigant CE; Cohen J; Vivera M; Zaltzman JS
Am J Kidney Dis; 2000 Jan; 35(1):58-63. PubMed ID: 10620545
[TBL] [Abstract][Full Text] [Related]
15. Comparative risk for angioedema associated with the use of drugs that target the renin-angiotensin-aldosterone system.
Toh S; Reichman ME; Houstoun M; Ross Southworth M; Ding X; Hernandez AF; Levenson M; Li L; McCloskey C; Shoaibi A; Wu E; Zornberg G; Hennessy S
Arch Intern Med; 2012 Nov; 172(20):1582-9. PubMed ID: 23147456
[TBL] [Abstract][Full Text] [Related]
16. A comparison between angiotensin converting enzyme inhibitors and angiotensin receptor blockers on end stage renal disease and major adverse cardiovascular events in diabetic patients: a population-based dynamic cohort study in Taiwan.
Wu LS; Chang SH; Chang GJ; Liu JR; Chan YH; Lee HF; Wen MS; Chen WJ; Yeh YH; Kuo CT; See LC
Cardiovasc Diabetol; 2016 Apr; 15():56. PubMed ID: 27039185
[TBL] [Abstract][Full Text] [Related]
17. Perioperative management of patients treated with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers: a quality improvement audit.
Vijay A; Grover A; Coulson TG; Myles PS
Anaesth Intensive Care; 2016 May; 44(3):346-52. PubMed ID: 27246933
[TBL] [Abstract][Full Text] [Related]
18. Comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on major adverse cardiac events in patients with newly diagnosed type 2 diabetes: a nationwide study.
Shih CJ; Chu H; Ou SM; Chen YT
Int J Cardiol; 2015 Nov; 199():283-9. PubMed ID: 26218587
[TBL] [Abstract][Full Text] [Related]
19. Primary prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with end-stage renal disease undergoing dialysis.
Lin TT; Yang YH; Liao MT; Tsai CT; Hwang JJ; Chiang FT; Chen PC; Lin JL; Lin LY
Kidney Int; 2015 Aug; 88(2):378-85. PubMed ID: 25807037
[TBL] [Abstract][Full Text] [Related]
20. Prognostic impact of renin-angiotensin system blockade in esophageal squamous cell carcinoma.
Chen YH; Huang CH; Lu HI; Chen CH; Huang WT; Hsieh MJ; Rau KM; Chang AY; Lin WC; Li SH
J Renin Angiotensin Aldosterone Syst; 2015 Dec; 16(4):1185-92. PubMed ID: 24961505
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
